FATE - Fate Therapeutics, Inc. News

Sectors

FATE

Fate Therapeutics, Inc.

2.62

14 x 2.62

7 x 2.63

bid

ask

0.21

7.42%

01:05 PM

timesize

Ytd	166.64%
1y	111.29%

2.61

day range

2.82

0.91

52 week range

3.23

Open	2.80	Prev Close	2.83	Low	2.61	High	2.82	Mkt Cap	329.86M
Vol	768.62K	Avg Vol	4.12M	EPS	-1.09	P/E	-2.60	Forward P/E	-0.99
Beta	2.51	Short Ratio	3.10	Inst. Own	102.25%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-11	50-d Avg	2.37	200-d Avg	1.53	1yr Est	6.31

FATE News

benzinga.com

Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sess

US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales

benzinga.com

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

Fate Therapeutics' Receives FDA Clearance For Its New Drug Application For FT839

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product C

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Mul

benzinga.com

Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Soc

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Can

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

globenewswire.com

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

seekingalpha.com

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on F

globenewswire.com

Fate Therapeutics Appoints Laura Hamill to Board of Directors

SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

benzinga.com

HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu

benzinga.com

Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatol

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

globenewswire.com

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatol

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21

globenewswire.com

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

globenewswire.com

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annua

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemothera

prnewswire.com

The $13 Million Company Teaching the Immune System to Hunt Cancer

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

benzinga.com

Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annu

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-th

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage

zacks.com

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensu

benzinga.com

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys

globenewswire.com

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refracto

benzinga.com

Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of G

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemother

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity

benzinga.com

10 Health Care Stocks Whale Activity In Today's Session

benzinga.com

Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Dev

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readi

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supp

benzinga.com

Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus

globenewswire.com

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-th

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage

benzinga.com

HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy

globenewswire.com

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage

benzinga.com

Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumato

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

globenewswire.com

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate fo

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

benzinga.com

Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 369 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 647 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Thursday

During the session on Thursday, 461 stocks hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 241 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Monday

Monday saw 196 companies set new 52-week lows.

benzinga.com

Earnings Scheduled For August 3, 2022

Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua

benzinga.com

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

benzinga.com

Earnings Scheduled For November 4, 2021

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

benzinga.com

Stocks That Hit 52-Week Highs On Wednesday

benzinga.com

Stocks That Hit 52-Week Highs On Thursday